secwatch / observer
8-K filed February 21, 2023, 6:59 PM ET ticker MED CIK 0000910329
earnings confidence high sentiment negative materiality 0.75

Medifast Q4 revenue down 10.7% to $337.2M; guides Q1 revenue $300-320M

MEDIFAST INC

2022-FY EPS reported $12.73 revenue$1,598,577,000

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

MEDIFAST INC reported the fiscal year ended December 31, 2022 results: revenue $1.6 billion, net income $143.6 million, EPS $12.73 per diluted share. Guidance reaffirmed.

Period
the fiscal year ended December 31, 2022
Revenue
$1.6 billion
Net income
$143.6 million
EPS
$12.73 per diluted share
Guidance
reaffirmed
Result
reported results
Exact text from the filing
For the fiscal year ended December 31, 2022, revenue increased 4.8% to $1.6 billion compared to revenue of $1.5 billion in 2021.
View on SEC.gov
Earnings Releases SEC 8-K Item 2.02 confidence 0.95

MEDIFAST INC reported the fourth quarter ended December 31, 2022 results: revenue $337.2 million, net income $26.5 million, EPS $2.41 per diluted share.

Period
the fourth quarter ended December 31, 2022
Revenue
$337.2 million
Net income
$26.5 million
EPS
$2.41 per diluted share
Result
reported results
Exact text from the filing
one of the fastest-growing health and wellness communities, OPTA VIA® , today reported results for the fourth quarter ended December 31, 2022. Fourth Quarter 2022 • Revenue of $337.2 million, with revenue per active earning coach of $5,538 • Independent active earning OPTA VIA Coaches of 60,900 • Net income of $26.5 million (non-GAAP adjusted net income of $40.6
View on SEC.gov

44 earnings releases filed in the last 30 days. Browse all earnings releases →

MEDIFAST INC filing history →

Source: SEC EDGAR
accession 0001628280-23-004295
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.